Immune Thrombocytopenia clinical trials at UCLA
1 research study open to eligible people
Showing trials for
Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP)
open to eligible people ages 18 years and up
The purpose of this study is to investigate the tolerability of ianalumab (9 mg/kg) with investigator's choice thrombopoietin receptor agonist (IC TPO-RA) in participants diagnosed with primary immune thrombocytopenia (ITP) who have been treated with at least one but no more than four prior treatments, and with no change in IC TPO-RA dose in at least the last 14 days prior to the start of ianalumab.
Torrance, California and other locations
Our lead scientists for Immune Thrombocytopenia research studies include Sarah Tomassetti.
Last updated: